WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558133
CAS#: 373641-87-3
Description: KAT-681 is a liver-selective thyromimetic.
Hodoodo Cat#: H558133
Name: KAT-681
CAS#: 373641-87-3
Chemical Formula: C24H21FNNaO6
Exact Mass: 0.00
Molecular Weight: 461.420
Elemental Analysis: C, 62.47; H, 4.59; F, 4.12; N, 3.04; Na, 4.98; O, 20.80
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: T 0681; T-0681; T0681;
IUPAC/Chemical Name: Propanoic acid, 3-((4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl)amino)-3-oxo-, monosodium salt
InChi Key: WIAUUVBWUTVDDD-UHFFFAOYSA-M
InChi Code: InChI=1S/C24H22FNO6.Na/c1-13-9-17(26-21(28)12-22(29)30)10-14(2)24(13)32-18-7-8-20(27)19(11-18)23(31)15-3-5-16(25)6-4-15;/h3-11,23,27,31H,12H2,1-2H3,(H,26,28)(H,29,30);/q;+1/p-1
SMILES Code: O=C([O-])CC(NC1=CC(C)=C(OC2=CC=C(O)C(C(C3=CC=C(F)C=C3)O)=C2)C(C)=C1)=O.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 461.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Hayashi M, Ohnota H, Tamura T, Kuroda J, Shibata N, Akahane M, Moriwaki H, Machida N, Mitsumori K. Inhibitory effects of KAT-681, a liver-selective thyromimetic, on development of hepatocellular proliferative lesions in rats induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Arch Toxicol. 2004 Aug;78(8):460-6. Epub 2004 Mar 19. PubMed PMID: 15034639.
2: Hayashi M, Tamura T, Kuroda J, Ohnota H, Shibata N, Akahane M, Kashida Y, Mitsumori K. Different inhibitory effects in the early and late phase of treatment with KAT-681, a liver-selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Toxicol Sci. 2005 Mar;84(1):22-8. Epub 2004 Nov 24. PubMed PMID: 15564315.
3: Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs. 2009 Sep;10(9):912-8. Review. PubMed PMID: 19705333; PubMed Central PMCID: PMC2993058.
4: Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res. 2009 May;50(5):938-44. doi: 10.1194/jlr.M800553-JLR200. Epub 2008 Dec 22. PubMed PMID: 19106072; PubMed Central PMCID: PMC2666180.
5: Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722. PubMed PMID: 20090943; PubMed Central PMCID: PMC2806908.